Treatment of RA with medications that inhibit specific inflammatory cytokines, such as interleukin (IL-6) and tumor necrosis factor alpha (TNFa), has been shown to prevent bone loss, remarkably both in responders and non-responders, and to improve BMD in some studies of experimental design [30–32]. The gene discussed is TNF; the disease is rheumatoid arthritis.